Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Status:
Completed
Trial end date:
2018-12-23
Target enrollment:
Participant gender:
Summary
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra
standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)
measuring the effects on the acute rise and fall of the plasma C reactive protein levels
during the first 14 days.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)